TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06466005

Intervention type: OTHER
Intervention: UnityPhilly app
Description: UnityPhilly automatically connects bystanders and victims of opioid overdose with nearby community members who can respond immediately with naloxone.

Intervention type: OTHER
Intervention: UnityPhilly app
Description: UnityPhilly automatically connects bystanders and victims of opioid overdose with nearby community members who can respond immediately with naloxone.

Intervention type: OTHER
Intervention: UnityPhilly app
Description: UnityPhilly automatically connects bystanders and victims of opioid overdose with nearby community members who can respond immediately with naloxone.
Study: NCT05562453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlowOx 2.0
Description: Subjects randomized to tretament with the investigational device will receive treatment with -40 mmHg intermittent negative pressure for 60 minutes per day.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: FlowOx2.0 (Sham)
Description: Subjects randomized to treatment with the comparator will receive treatment with -10 mmHg intermittent negative pressure for 60 minutes per day.
Study: NCT06348524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol injection
Description: ferumoxytol will assess patency of coronary arteries
Study: NCT05276076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM-001 1X10^6 cells/kg
Description: Administration: Inject intravenously single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM-001 3X10^6 cells/kg
Description: Administration: Inject intravenously single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM-001 5X10^6 cells/kg
Description: Administration: Inject intravenously single dose
Study: NCT06536504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steinway Spirio M recording/player piano
Description: Patients will be equally randomized into one of the three arms (simulated live music, recorded music, or no music) applying the random permutated block. Randomization will be conducted via an approved institutional database with the randomization list generated by the study statistician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steinway Spirio M recording/player piano
Description: Patients will be equally randomized into one of the three arms (simulated live music, recorded music, or no music) applying the random permutated block. Randomization will be conducted via an approved institutional database with the randomization list generated by the study statistician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steinway Spirio M recording/player piano
Description: Patients will be equally randomized into one of the three arms (simulated live music, recorded music, or no music) applying the random permutated block. Randomization will be conducted via an approved institutional database with the randomization list generated by the study statistician.
Study: NCT04836793

Intervention type: OTHER
Intervention: Additional biological samples
Description: Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected

Intervention type: OTHER
Intervention: Additional biological samples
Description: Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected

Intervention type: OTHER
Intervention: Additional biological samples
Description: Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected
Study: NCT05742984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaprazan Glurate 25 mg
Description: The participating subjects will receive 25 mg doses of IMP, QD or BID for 14 days. After a drug holiday period (2, 4 or 6 days), linaprazan glurate will be given once more (QD or BID, on Day 16, 18 or 20). In total, 15 or 30 doses will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaprazan Glurate 25 mg
Description: The participating subjects will receive 25 mg doses of IMP, QD or BID for 14 days. After a drug holiday period (2, 4 or 6 days), linaprazan glurate will be given once more (QD or BID, on Day 16, 18 or 20). In total, 15 or 30 doses will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaprazan Glurate 50 mg
Description: The participating subjects will receive 50 mg doses of IMP, QD or BID for 14 days. After a drug holiday period (2, 4 or 6 days), linaprazan glurate will be given once more (QD or BID, on Day 16, 18 or 20). In total, 15 or 30 doses will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaprazan Glurate 50 mg
Description: The participating subjects will receive 50 mg doses of IMP, QD or BID for 14 days. After a drug holiday period (2, 4 or 6 days), linaprazan glurate will be given once more (QD or BID, on Day 16, 18 or 20). In total, 15 or 30 doses will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaprazan Glurate 75 mg
Description: The participating subjects will receive 75 mg doses of IMP, QD or BID for 14 days. After a drug holiday period (2, 4 or 6 days), linaprazan glurate will be given once more (QD or BID, on Day 16, 18 or 20). In total, 15 or 30 doses will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaprazan Glurate 75 mg
Description: The participating subjects will receive 75 mg doses of IMP, QD or BID for 14 days. After a drug holiday period (2, 4 or 6 days), linaprazan glurate will be given once more (QD or BID, on Day 16, 18 or 20). In total, 15 or 30 doses will be given.
Study: NCT06693492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound technique for diagnosis; Focused Ultrasound Stimulation for intervention
Description: Both chronic and post-acute patients are evaluated through the ultrasound technique to further characterize the mechanisms underlying DOC following acquired brain injuries (e.g., stroke, traumatic brain injury, anoxic events). Furthermore, the predictive value of structural and functional markers for DOC chronicization is explored by following up post-acute DOC patients 1 year after the acute event. Finally, to innovate the therapeutic approach to DOC patients, we adopt the low-intensity focused ultrasound (FUS) on a group of selected 10 patients out of the 100 DOC patients enrolled in the study to modulate brain networks' functioning targeting key brain structures for the recovery of consciousness.
Study: NCT04588285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol
Description: Oral ambroxol medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)
Study: NCT06487975

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bacillus Subtilis
Description: Bacillus Subtilis 1 capsule once daily in the morning (consisting of 10x10\^9 Colony Forming Units)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 visually identical placebo capsule once daily in the morning using the same carrier (microcrystalline cellulose) as the active (but not containing Bacillus Subtilis)
Study: NCT06327425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetocardiography
Description: Magnetocardiography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetocardiography
Description: Magnetocardiography
Study: NCT05855694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THOR LED Photobiomodulation Helmet - Therapeutic
Description: Photobiomodulation (PBM) is a non-invasive treatment option that uses nonionizing light sources such as laser diodes and light-emitting diodes in the visible and near-infrared spectrum.~Each participant will be required to sit with the helmet device over their head for the length of their study session. Participants and study staff will wear protective goggles throughout each session. These goggles help to block out any red LED light emitted from the helmet device. Participants may experience a pleasant warmth upon their head during both the therapeutic and control settings.~Helmet will be in 'therapeutic setting' of 35mW/cm2 = 42J/cm2

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: THOR LED Photobiomodulation Helmet - Control
Description: Each participant will be required to sit with the helmet device over their head for the length of their study session. Participants and study staff will wear protective goggles throughout each session. These goggles help to block out any red LED light emitted from the helmet device. Participants may experience a pleasant warmth upon their head during both the therapeutic and control settings.~Helmet will be in 'non-therapeutic setting' of 0mW/cm2 = 0J/cm2
Study: NCT05453539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSPE-DOTA-Gd Liposomal Injection
Description: Single dose, intravenous infusion
Study: NCT04920344

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transoral Surgery
Description: Patients will undergo transoral surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral Surgery
Description: Patients will undergo transoral surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral Surgery
Description: Patients will undergo transoral surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Patients in Group II and Group III will undergo External Beam Radiation Therapy (EBRT) RT following transoral surgery.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Patients in Group II and Group III will undergo External Beam Radiation Therapy (EBRT) RT following transoral surgery.
Study: NCT06691945

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Saline delivered using an intrauterine pressure catheter (IUPC)
Description: An intrauterine pressure catheter (IUPC) will be placed in participants after membrane rupture, or at 4 cm if membranes previously ruptured. A 300cc bolus of normal saline will be administered. A continuous rate of 100 cc/hr of normal saline will continue until delivery to prevent Postpartum Hemorrhage. If the IUPC is dislodged, it will be replaced by a trained clinician.
Study: NCT06688435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYS6020 injection
Description: The SYS6020 is an injection of autologous CAR-T cells that have been temporarily transfected with LNP-mRNA targeting BCMA. Before each dosing, the infusion eligibility of SYS6020 is assessed by the investigator, and the eligible participants will receive 3 dosing SYS6020 injection treatment. The dosing interval is 7 days or 28 days according to the protocol design.
Study: NCT04920344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients in Group III will receive cisplatin, 30 mg/m2, administered intravenously weekly per for 6 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incisional Tumor Biopsy
Description: Incisional biopsy of the primary tumor site will be required to confirm p16/HPV status of the tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incisional Tumor Biopsy
Description: Incisional biopsy of the primary tumor site will be required to confirm p16/HPV status of the tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incisional Tumor Biopsy
Description: Incisional biopsy of the primary tumor site will be required to confirm p16/HPV status of the tumor
Study: NCT04920344

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Circulating tumor deoxyribonucleic acid (ctDNA) levels assessment
Description: Assess ctDNA levels at baseline, 2 weeks, 4 weeks, 10 weeks, 24 weeks and 1 year after the surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circulating tumor deoxyribonucleic acid (ctDNA) levels assessment
Description: Assess ctDNA levels at baseline, 2 weeks, 4 weeks, 10 weeks, 24 weeks and 1 year after the surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circulating tumor deoxyribonucleic acid (ctDNA) levels assessment
Description: Assess ctDNA levels at baseline, 2 weeks, 4 weeks, 10 weeks, 24 weeks and 1 year after the surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MD Anderson Dysphagia Index
Description: MDADI is a 20 item quality of life questionnaire specifically focusing on swallowing aspects. It was originally designed for head and neck cancer patients. The total score ranges from 20 to 100 with the higher score indicating higher level of function.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MD Anderson Dysphagia Index
Description: MDADI is a 20 item quality of life questionnaire specifically focusing on swallowing aspects. It was originally designed for head and neck cancer patients. The total score ranges from 20 to 100 with the higher score indicating higher level of function.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MD Anderson Dysphagia Index
Description: MDADI is a 20 item quality of life questionnaire specifically focusing on swallowing aspects. It was originally designed for head and neck cancer patients. The total score ranges from 20 to 100 with the higher score indicating higher level of function.
Study: NCT05453539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSPE-DOTA-Gd Liposomal Injection
Description: Single dose, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSPE-DOTA-Gd Liposomal Injection
Description: Single dose, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSPE-DOTA-Gd Liposomal Injection
Description: Single dose, intravenous infusion
Study: NCT05276076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM-001 1X10^6 cells/kg two dose
Description: Administration: Inject intravenously~1X10\^6 cells/kg per dose, two dose in total, weekly
Study: NCT04920344

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: University of Washington Quality of Life Questionnaire
Description: University of Washington Questionnaire is a 15 item quality of life instrument specifically designed for head and neck cancer patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: University of Washington Quality of Life Questionnaire
Description: University of Washington Questionnaire is a 15 item quality of life instrument specifically designed for head and neck cancer patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: University of Washington Quality of Life Questionnaire
Description: University of Washington Questionnaire is a 15 item quality of life instrument specifically designed for head and neck cancer patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Euro-QOL 5 dimension scale questionnaire
Description: A generic quality of life and cost utility instrument widely used and validated for multiple disease settings, including head and neck cancer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Euro-QOL 5 dimension scale questionnaire
Description: A generic quality of life and cost utility instrument widely used and validated for multiple disease settings, including head and neck cancer.
Study: NCT05276076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM-001 1X10^6 cells/kg four dose
Description: Administration: Inject intravenously~1X10\^6 cells/kg per dose, four dose in total, weekly
Study: NCT04920344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Euro-QOL 5 dimension scale questionnaire
Description: A generic quality of life and cost utility instrument widely used and validated for multiple disease settings, including head and neck cancer.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Modified barium swallow (MBS) evaluation with aspiration-penetration scale
Description: The videofluoroscopic modified barium swallow (MBS) study is the gold standard for for the evaluation of dysphagia, and specifically, airway protective mechanisms.~The penetration/aspiration (PEN/ASP) scale is a routinely used eight-point scale designed to describe the depth of bolus penetration into the airway and the patient response to the penetration or aspiration.
Study: NCT05987540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive brainstem stimulation
Description: Study participants will self-administer \~19-minute treatments twice daily in the home setting over 12 weeks using a non-invasive brainstem modulation device.
Study: NCT04920344

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Modified barium swallow (MBS) evaluation with aspiration-penetration scale
Description: The videofluoroscopic modified barium swallow (MBS) study is the gold standard for for the evaluation of dysphagia, and specifically, airway protective mechanisms.~The penetration/aspiration (PEN/ASP) scale is a routinely used eight-point scale designed to describe the depth of bolus penetration into the airway and the patient response to the penetration or aspiration.
Study: NCT06688435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYS6020 injection
Description: The SYS6020 is an injection of autologous CAR-T cells that have been temporarily transfected with LNP-mRNA targeting BCMA. Before each dosing, the infusion eligibility of SYS6020 is assessed by the investigator, and the eligible participants will receive 3 dosing SYS6020 injection treatment. The dosing interval is 7 days or 28 days according to the protocol design.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYS6020 injection
Description: The SYS6020 is an injection of autologous CAR-T cells that have been temporarily transfected with LNP-mRNA targeting BCMA. Before each dosing, the infusion eligibility of SYS6020 is assessed by the investigator, and the eligible participants will receive 3 dosing SYS6020 injection treatment. The dosing interval is 7 days or 28 days according to the protocol design.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYS6020 injection
Description: The SYS6020 is an injection of autologous CAR-T cells that have been temporarily transfected with LNP-mRNA targeting BCMA. Before each dosing, the infusion eligibility of SYS6020 is assessed by the investigator, and the eligible participants will receive 3 dosing SYS6020 injection treatment. The dosing interval is 7 days or 28 days according to the protocol design.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYS6020 injection
Description: The SYS6020 is an injection of autologous CAR-T cells that have been temporarily transfected with LNP-mRNA targeting BCMA. Before each dosing, the infusion eligibility of SYS6020 is assessed by the investigator, and the eligible participants will receive 3 dosing SYS6020 injection treatment. The dosing interval is 7 days or 28 days according to the protocol design.
Study: NCT06726018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditioned Pain Modulation (CPM)
Description: Participants will receive a testing stimulus of pressure applied per ascending intensity at the web space of the foot until the pain reaches 40 out of 100, then discontinued. After testing the stimulus, participants will then receive a conditioning stimulus by immersing the non-dominant hand into the water-cooled by refrigeration unit with a temperature of 6 degree Celsius (males) or 8 degree Celsius (females) for 60 seconds. Subjects will be asked to rate the cold pain during the four 60-second trials. Participants completely removed their hand from the cold pressor for 30 seconds following each of the four 60-second immersions, during which time the testing stimulus will be re-applied per the sequential paradigm to the web space of the foot. Participants complete four 60-second periods of immersion.
Study: NCT05220891

Intervention type: OTHER
Intervention: Paracentesis
Description: Paracentesis from ascitic patient

Intervention type: OTHER
Intervention: Paracentesis
Description: Paracentesis from ascitic patient
Study: NCT04353258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economics intervention (BE mHealth)
Description: Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth) that includes behavioral economics components.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard mHealth intervention (mHealth)
Description: Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth).
Study: NCT06344247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAS inhibitors：Losartan®️/Valsartan®️
Description: Losartan®️/Valsartan®️ : maintain the maximum dose/maximum tolerated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAS inhibitors：Losartan®️/Valsartan®️
Description: Losartan®️/Valsartan®️ : maintain the maximum dose/maximum tolerated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAS inhibitors：Losartan®️/Valsartan®️
Description: Losartan®️/Valsartan®️ : maintain the maximum dose/maximum tolerated dose.
Study: NCT06726018

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conditioned Pain Modulation (CPM)
Description: Participants will receive a testing stimulus of pressure applied per ascending intensity at the web space of the foot until the pain reaches 40 out of 100, then discontinued. After testing the stimulus, participants will then receive a conditioning stimulus by immersing the non-dominant hand into the water-cooled by refrigeration unit with a temperature of 6 degree Celsius (males) or 8 degree Celsius (females) for 60 seconds. Subjects will be asked to rate the cold pain during the four 60-second trials. Participants completely removed their hand from the cold pressor for 30 seconds following each of the four 60-second immersions, during which time the testing stimulus will be re-applied per the sequential paradigm to the web space of the foot. Participants complete four 60-second periods of immersion.
Study: NCT05934578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Aerobic and light muscle resistance exercise by online cardiovascular rehabilitation
Study: NCT06344247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAS inhibitors：Losartan®️/Valsartan®️
Description: Losartan®️/Valsartan®️ : maintain the maximum dose/maximum tolerated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin：Forxiga®️
Description: Forxiga®️ : titrated to the target dose (10 mg qd).
Study: NCT06746584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: benson relaxation exercise
Description: BRT is one of the behavioural intervention techniques developed by Herbert Benson in 1975. BRT is based on the principle of deep breathing and relaxing all the muscles in the body by choosing a word that is meaningful for the individual and focusing on it. This exercise, which has no side effects on patients and can be applied for patients of all age groups, is more widely used because it is a simple and easy-to-learn method compared to other relaxation methods all the muscles in the body by choosing a word that is meaningful for the individual and focusing on it.